Chinese yellow wine and red wine inhibit matrix metalloproteinase-2 and improve atherosclerotic plaque in LDL receptor knockout mice.
Our previous study found that Chinese yellow wine could inhibit the production of homocysteine (HCY) induced extracellular matrix metalloproteinase-2 (MMP-2) in the cultured rat vascular smooth muscle cells. Little is known about the relationship between Chinese yellow wine and atherosclerosis or MMP-2 in vivo. Thirty-two LDL Receptor knockout mice on a high-fat and L-methionine diet developed plasma hyperhomocysteinemia and atherosclerosis. They were randomly divided into yellow wine group (n = 8), red wine group (n = 8), ethanol group (n = 8), and control group (n = 8), they were sacrificed after 14 weeks. There were no significant differences with plasma total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels in the four groups. Plasma HCY was significantly decreased in the yellow wine group compared to the other three groups (P < 0.01). Yellow wine and red wine groups significantly reduced the atherosclerosis lesion area compared to ethanol and control groups (P < 0.001). However, there was no significant discrepancy between the yellow wine group and red wine group. Compared to the control group and ethanol group, the production of MMP-2 reduced 26.8% and 23.6% in the aortic sinus and the activation of MMP-2 reduced 32.6% and 27.3% in the aortic arch in the yellow wine group; the production of MMP-2 reduced 25.7% and 22.4% in the aortic sinus and the activation of MMP-2 reduced 30.2% and 26.6% in the aortic arch in the red wine group. These results suggest that Chinese yellow wine and red wine can inhibit MMP-2 and improve atherosclerosis, and maybe both Chinese yellow wine and red wine have beneficial effects on cardiovascular disease by inhibiting MMP-2.
Guo
Hangyuan
H
Department of Cardiology, Shaoxing People's Hospital, the First Affiliated Hospital of Shaoxing University, Zhejiang, 312000 China. ghangyuan@hotmail.com
Liu
Longbin
L
Shi
Yafei
Y
Sun
Aijing
A
Xu
Fukang
F
Chi
Jufang
J
Huang
Dilai
D
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001018:Aortic Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D001219:Aspartate Aminotransferases / Q000097:blood; D050197:Atherosclerosis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D015415:Biomarkers / Q000097:blood; D002681:China; D004195:Disease Models, Animal; D004789:Enzyme Activation; D006710:Homocysteine / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D061965:Matrix Metalloproteinase Inhibitors; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011480:Protease Inhibitors / Q000494:pharmacology*; D011973:Receptors, LDL / Q000172:deficiency* / Q000235:genetics; D014920:Wine
D015415:Biomarkers; D008055:Lipids; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D011973:Receptors, LDL; D006710:Homocysteine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D020778:Matrix Metalloproteinase 2; C522362:Mmp2 protein, mouse